论文部分内容阅读
本刊讯钱江生化近日“剧透”了重组框架,拟以非公开发行股份及支付现金的方式收购江苏宝众宝达药业有限公司(以下简称宝众宝达)控制权,同时募集配套资金。本次交易对手系香港瑞华药业国际有限公司,不会导致公司实际控制人发生变更。公告显示,宝众宝达是由香港瑞华药业国际有限公司在内地投资建立的一家综合性药企,属省级高新技术企业,主要从事医药、兽药、农药等精细化学品的研发、
Journalism Qianjiang Biochemical recently “Spit through ” the restructuring framework, intended to be non-public offering of shares and payment of cash to acquire Jiangsu Baozhong Po Tat Pharmaceutical Co., Ltd. (hereinafter referred to Baozhong Po Tat) control, at the same time Raise matching funds. The counterparty of Hong Kong Ruihua Pharmaceutical International Co., Ltd., will not result in the actual controller of the company changed. The announcement shows that Baozhong BaoDa is a comprehensive pharmaceutical enterprise invested and established by Hong Kong Ruihua Pharmaceutical International Co., Ltd. in the Mainland. It is a provincial-level high-tech enterprise engaged in the research and development of fine chemicals such as medicine, veterinary drugs and pesticides.